How to appeal an Aetna cystic fibrosis & pulmonary fibrosis denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for cystic fibrosis & pulmonary fibrosis

Cited policy: Aetna Clinical Policy Bulletin (Cystic Fibrosis Modulator Therapy)

Defines covered modulators by mutation. Lags FDA label updates by months.

How Aetna denies cystic fibrosis & pulmonary fibrosis — and how to counter it

Where Aetna pushes back: 1) CPB references older FDA label; 2) Pediatric (age 2-5) denied; 3) 'Experimental' for non-F508del responsive.

Counter-arguments that hold up: Cite current FDA label date and CFF 2023 update if CPB references older guidance; request medical exception. Trikafta FDA approved age 2-5 in April 2023 based on VX20-445-111. FDA expanded label in 2020 and 2024 to cover additional responsive mutations based on in vitro theratyping (HBE cell assay).

What Aetna typically denies for cystic fibrosis & pulmonary fibrosis

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For cystic fibrosis & pulmonary fibrosis, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the cystic fibrosis & pulmonary fibrosis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Trikafta
• Symdeko
• Orkambi
• Kalydeco
• Pulmozyme
• Hypertonic saline

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.